CHANGES TO THE SPECIFICATION

Please replace the paragraph beginning at page 4, line 5 with the following paragraph:

-- This invention relates to compounds comprising of the formula I:

$$\begin{array}{c|c}
G_1 & O & N \\
\hline
O & O & G_2 \\
\hline
O & O & G_3
\end{array}$$

wherein:

G¹ is-selected from the group consisting of a, b¹ and b²

A is selected from the group phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, and thienyl, all optionally substituted with lower alkyl, halogen, haloalkyl, alkoxy, cyano, nitro, -SO₂R', -NSO₂R', -SO₂NR'R", -NR'R", or -COR'; R' and R" are each independently hydrogen or lower alkyl;

 G^2 is selected from the group represented by the Formula \underline{c} , \underline{d} , \underline{e} , and \underline{f}

COOH
$$()_{n} \cdot \text{COOH}$$

$$()_{n} \cdot \text{COOH}$$

$$()_{n} \cdot \text{N}$$

$$($$

COOH
$$()_{n} COOH$$

$$()_{n} COOH$$

$$()_{n} R^{1}$$

$$R^{2}$$

R¹ and R² are independently in each occurrence selected from the group consisting of hydrogen, lower alkyl, halogen, haloalkyl, nitro, -NR'R", -OR', -NR'SO₂R", -SO₂R', -COR', cyano, nitro, phenyl (optionally substituted with halo, alkyl, cyano, nitro, or alkoxy), or heteroaryl (optionally substituted with halo, alkyl, cyano, nitro or alkoxy); and wherein R' and R" are as defined hereinbefore;

R¹ and R², if adjacent, taken together with the carbons to which they are attached may also form an aromatic ring, optionally substituted with one or two substitutents selected from the group consisting of lower alkyl, halo, cyano, or lower alkoxy;

n is an integer selected from 0, 1, 2 and 3; or prodrugs, or pharmaccutically acceptable salts or solvates thereof:--

Please replace the paragraph beginning at p. 5 line 19 with the following paragraph:

--In another aspect, the invention relates to a process for preparing a compound of Formula I wherein G^2 is a group represented by the formulae $\underline{\mathbf{c}}$ or $\underline{\mathbf{d}}$, which comprises: esterification of the compounds having a general Formula $\underline{\mathbf{2}}$ or $\underline{\mathbf{3}}$:

COOH
$$()_{n} \stackrel{\text{COOH}}{\longrightarrow} R^{1}$$
or
$$R^{2}$$

$$R^{2}$$

$$R^{3}$$

ROCHE BIOSCIENCE PAT

wherein n, R¹ and R² are as defined herein, acylation with phosgene, followed by reaction with a compound of general Formula 1

JAN 16'04

wherein G1 is as defined herein, and hydrolysis, to provide a compound of the general Formula Ia or Ib

G'ON G'ON G'ON COOH

$$\underline{a} \quad R^2 \quad R^1$$
 $\underline{a} \quad R^2 \quad R^1$
 $\underline{a} \quad R^2 \quad R^1$

wherein n, G1, R1, and R2 are as defined herein.--

Please replace the paragraph beginning at p. 6 line 10 with the following paragraph:

-- In another aspect, the invention relates to a process for preparing a compound of Formula I wherein G^2 is a group represented by the formulae \underline{c} or \underline{d} , which comprises: esterification of the compounds having a general Formula \underline{e} or \underline{f} which comprises: acylation with phosgene of a compound of general Formula em or co,

$$H_2N$$
 R^2
 R^1
 SO
 R^2
 R^1
 SO
 R^2
 R^1
 SO

followed by reaction with a compound of general Formula 2

wherein G1 is as defined herein,

and treatment with azide to provide a compound of general Formula le

wherein n, G1, R1, and R2 are as defined herein .--

Please replace the paragraph beginning at p. 25 line 10 with the following paragraph:

--Scheme C describes a method of preparing a compound of Formula I wherein G^2 is a compound represented by Formula \underline{e} or \underline{f} , wherein \underline{e} or \underline{f} , n, G^1 , R^1 , and R^2 , are as defined in the Summary of the Invention.

Please replace the paragraph beginning at p. 25 line 16 with the following paragraph:

--Generally as set forth in Scheme C, a certain amino-benzonitrile of general Formula <u>cm</u> can be acylated with phosgene in an inert solvent to give the isocyanate that can subsequently react with a hydroxymethanol of general Formula <u>1</u>, to give the carbamate of general Formula <u>en</u>, under similar conditions as described in Schemes A and B. Treatment of the nitrile group with sodium azide can yield the tetrazolyl derivative of general Formula Ic. Compounds of general Formula em, wherein R¹ is phenyl or heteroaryl can be prepared from the appropriate starting halo-amino-nitrile derivative with phenyl or heteroaryl boronic acid in the presence of a catalyst preferably tetrakistriphenylphosphine-palladium and a base such as sodium carbonate or potassium carbonate.

$$\begin{array}{c|c}
H_2N & & G^1 & O & N & N \\
\hline
\underline{co} & & R^2 & R^1 & & \underline{ld} & R^2 & R^1 & N \\
\hline
\underline{co} & & & \underline{ld} & & R^2 & R^1 & N \\
\underline{co} & & & \underline{ld} & & R^2 & R^1 & N \\
\underline{co} & & & \underline{ld} & & R^2 & R^1 & N \\
\hline
\underline{co} & & & \underline{ld} & & R^2 & R^1 & N \\
\hline
\underline{co} & & & \underline{ld} & & R^2 & R^1 & N \\
\hline
\underline{co} & & & \underline{ld} & & R^2 & R^1 & N \\
\hline
\underline{co} & & & \underline{ld} & & R^2 & R^1 & N \\
\hline
\underline{co} & & & \underline{ld} & & R^2 & R^1 & N \\
\hline
\underline{co} & & & \underline{ld} & & R^2 & R^1 & N \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} \\
\underline{co} & & & \underline{co} \\
\hline
\underline{co} & & & \underline{co} \\
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\underline{co} & & & \underline{co} \\
\underline{co} & & & \underline{co} \\
\underline{co} & & & \underline{co} & & \underline{co} & & \underline{co} & & \underline{co} \\
\underline{co} & & & \underline{co} & &$$

Please replace the paragraph beginning at p. 38, line 1 with the following paragraph:

--Example 1

4-(5-Phenyl-benzofuran-2-ylmethoxycarbonylamino)-biphenyl-3-carboxylic Acid

Please replace the paragraph beginning at p. 42, line 4 with the following paragraph:

--Example 2


2-(5-Phenyl-benzofuran-2-ylmethoxycarbonylamino)-naphthalene-1-carboxylic Acid

Please replace the paragraph beginning at p. 44, line 19 with the following paragraph:

--Example 3 2-[5-(4-Fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-5-isopropoxy-benzoic Acid

Please replace the paragraph beginning at p. 46, line 1 with the following paragraph:

--<u>Example 4</u> 5-(5-Phenyl-benzofuran-2-ylmethoxycarbonylamino)-biphenyl-3-carboxylic Acid



Please replace the paragraph beginning at p. 48, line 20 with the following paragraph:

--Example 5
3-(111-Tetrazol-5-yl)-biphenyl-4-yl-carbamic Acid 5-phenyl-benzofuran-2-ylmethyl ester

Please replace the paragraph beginning at p. 51, line 1 with the following paragraph:

-- Example 6 4-(Biphenyl-4-ylmethoxycarbonylamino)-biphenyl-3-carboxylic Acid

Please replace the paragraph beginning at p. 52, line 1 with the following paragraph:

--Example 7

2-Amino-6-[5-(4-fluoro-phenyl)-benzofuran-2-ylmethoxycarbonylamino]-benzoi- c Acid

Please replace the paragraph beginning at p. 53, line 4 with the following paragraph:

--<u>Example 8</u> 2-[2-(Biphenyl-4-yloxy)-cthoxycarbonylamino]-6-chloro-benzoic Acid